Cipla LtdOTC Pink - Limited Information:CPLFY
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0009/ 100
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0000
- Day Range---
- 52 Week Range---
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Oct 29, 2024
*DJ Cipla 2Q Net INR13.02B Vs. Net INR11.31B >500087.BY, from 4:56AM ET on Tuesday Oct 29, 2024 by Dow Jones
4:56AM ET on Tuesday Oct 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cipla Ltd | 14.0B | 0.0x | --- |
Incannex Healthcare Inc | 34.8M | -1.4x | --- |
TherapeuticsMD Inc | 15.3M | -3.9x | --- |
Healthy Extracts Inc | 6.7M | -8.6x | --- |
Dbv Technologies SA | 55.1M | -0.4x | --- |
Scisparc Ltd | 3.0M | -0.2x | --- |
Company Information
Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.
Contact Information
- Headquarters
- Mumbai CentralMUMBAI, India 400013
- Phone
- 222-482-6000
- Fax
- 222-482-6120
Executives
- Non-Executive Chairman of the Board
- Yusuf Hamied
- Global Chief Executive Officer, Managing Director, Executive Director
- Umang Vohra
- Global Chief Financial Officer
- Ashish Adukia
- Chief Information Officer
- Sneha Hiranandani
- Compliance Officer, Company Secretary
- Rajendra Chopra
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.0B |
|---|---|
Revenue (TTM) | $274.9M |
Shares Outstanding | 807.6M |
Cipla Ltd does not pay a dividend. | |
Beta | --- |
EPS | $0.04 |
Book Value | $0.61 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 51.0 |
Price/Cash Flow (TTM) | 255.1x |
Operating Margin | 22.16% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
